Summary: Retatrutide is an unlicensed investigational drug in the UK, administered as a once-weekly subcutaneous injection only within approved clinical trials under medical supervision
MWN-101 is an Fc-fusion protein in Phase 2 since March 2024 - notably, MWN-101's Fc architecture suggests a longer half-life than a standard fatty-acid-conjugated peptide, which would support less-frequent-than-weekly dosing
The most common listed side effects include nausea, vomiting, and diarrhea
GLP-1 treatment for weight loss may turn out to be genuinely beneficial for your eczema, but it should be pursued primarily for its established indications and with realistic expectations about skin outcomes specifically
Food intake was calculated as an average over a period of 3 days
Nearly 72% of users reported that the program helped minimize medication side effects